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Battling metastasis through inhibition of cell motility is con-
sidered a promising approach to support cancer therapies. In
this context, Ena/VASP-depending signaling pathways, in partic-
ular interactions with their EVH1 domains, are promising targets
for pharmaceutical intervention. However, protein–protein inter-
actions involving proline-rich segments are notoriously difficult
to address by small molecules. Hence, structure-based design
efforts in combination with the chemical synthesis of additional
molecular entities are required. Building on a previously devel-
oped nonpeptidic micromolar inhibitor, we determined 22 crystal
structures of ENAH EVH1 in complex with inhibitors and ratio-
nally extended our library of conformationally defined proline-
derived modules (ProMs) to succeed in developing a nanomolar
inhibitor (Kd = 120 nM, MW = 734 Da). In contrast to the previ-
ous inhibitor, the optimized compounds reduced extravasation of
invasive breast cancer cells in a zebrafish model. This study rep-
resents an example of successful, structure-guided development
of low molecular weight inhibitors specifically and selectively
addressing a proline-rich sequence-recognizing domain that is
characterized by a shallow epitope lacking defined binding pock-
ets. The evolved high-affinity inhibitor may now serve as a
tool in validating the basic therapeutic concept, i.e., the sup-
pression of cancer metastasis by inhibiting a crucial protein–
protein interaction involved in actin filament processing and cell
migration.
protein–protein interactions | metastasis | small molecules |
peptide mimetics | proline-rich motif
Metastasis is a complex multistep process (1, 2) employing,among others, mechanisms governing actin cytoskeleton
dynamics involving integrin signaling and actin regulatory pro-
teins (3–5). So far, all approved antimetastatic drugs antagonize
integrins (6) or inhibit downstream kinases (7, 8) (SI Appendix,
Fig. S1). In the metastatic setting however, these drugs appear to
have only limited success (9–13) and 5-y survival is not increasing
satisfactorily (14, 15), making new approaches in antimetastatic
drug development essential to meet this urgent medical need.
The enabled/vasodilator stimulated phosphoprotein protein
family (Ena/VASP) acts as a crucial hub in cell migration by
linking actin filaments to invadopodia and focal adhesions (16–
22). Due to their role in the transformation of benign lesions
into invasive and metastatic cancer, Ena/VASP proteins are dis-
cussed as part of the invasive signature and as a marker of breast
carcinogenesis (23–25). At the advanced tumor stage, the pro-
tein family is overexpressed (26–28), which has been shown to
increase migration speed in vivo (29) and to potentiate invasive-
ness (30). Yet, no sufficiently potent probes to interfere with
Ena/VASP in vivo have been reported.
The three vertebrate Ena/VASP family members, enabled
homolog (ENAH), VASP, and Ena-VASP-like (EVL), share a
tripartite structural organization in which two Ena/VASP homol-
ogy domains (EVH1 and EVH2) are separated by a more
divergent proline-rich central part. Interactions of the EVH2
domain are involved in the elongation and protection of barbed-
end actin filaments from capping proteins and tetramerization
(31, 32). EVH1 folds into a structured globular domain that
interacts with proteins at focal adhesions (33), the leading edge
(34, 35), and invadopodia (36, 37) by recognizing the motif
[F/W/L/Y]PxφP (35, 38) (φ hydrophobic, x any; SI Appendix,
Fig. S3) in poly-L-proline type II helix (PPII) conformation.
In the course of our research into small molecules as poten-
tial inhibitors of protein–protein interactions (39) we recently
in silico designed and stereo-selectively synthesized scaffolds,
coined ProMs, which mimic pairs of prolines in PPII conforma-
tion (40). The modular combination of different ProMs thereby
allowed us to generate nonpeptidic secondary-structure mimetics
that fulfill the steric requirements of the addressed proline-rich
motif-recognizing domain (41–47). For the EVH1 domain, our
proof-of-concept study yielded a canonically binding, nontoxic,
Significance
Protein–protein interactions mediated by proline-rich motifs
are involved in regulation of many important signaling cas-
cades. These motifs belong to the most abundant recognition
motifs in the eukaryotic genome and preferentially adopt a left-
handed polyproline helix II, a secondary structure element that
has been notoriously difficult to mimic with small molecules.
Here, we present a structure-guided design effort yielding a
toolkit of chemical entities that enables rational construction of
selective small molecule inhibitors for these protein domains.
We succeeded in developing an inhibitor for the Ena/VASP pro-
tein family that is active in vivo and reduces extravasation of
invasive breast cancer cells in a zebrafish model.
Author contributions: M. Barone, P.t.D., H.-G.S., and R.K. designed research; M. Barone,
M.M., S.C., J.R., D.A., A.S., S.D., M.K., J.B., M.v.D., R.O., P.L., M. Beerbaum, K.M., Y.R., P.S.,
R.V., M.N., U.H., and H.O. performed research; M. Barone and R.O. analyzed data; and
M. Barone, R.O., H.O., P.t.D., H.-G.S., and R.K. wrote the paper.y
The authors declare no competing interest.y
This article is a PNAS Direct Submission.y
This open access article is distributed under Creative Commons Attribution-NonCommercial-
NoDerivatives License 4.0 (CC BY-NC-ND).y
1 To whom correspondence may be addressed. Email: kuehne@fmp-berlin.de, p.ten
dijke@lumc.nl, or schmalz@uni-koeln.de.y
This article contains supporting information online at https://www.pnas.org/lookup/suppl/
doi:10.1073/pnas.2007213117/-/DCSupplemental.y
First published November 12, 2020.

















































cell-membrane-permeable, 706-Da inhibitor 1 (Fig. 1A) com-
posed of two different ProM scaffolds and 2-chloro-(L)-
phenylalanine (2-Cl-Phe) (40). While the synthetic inhibitor
1 represents the compound with the highest reported affinity
toward Ena/VASP EVH1 domains, a further improvement was
required for in vivo experiments. Here we report successful
structure-based optimization of inhibitor 1 based on 22 high-
resolution crystal structures of ENAH EVH1 in complex with
different inhibitors (SI Appendix, Tables S1–S6), including the
well-resolved C-terminal binding epitope TEDEL of ActA from
Listeria monocytogenes (48). Newly identified interaction sites
adjacent to the C terminus of 1 were addressed by in silico
designed and stereo-selectively synthesized modifications of the
ProM-1 scaffold (Fig. 1A). While drastically increasing the affin-
ity against a rather flat protein surface we conserved structural
simplicity, low molecular weight, nontoxicity, and cell-membrane
permeability. Potent compounds against Ena/VASP were shown
to also act in vivo, i.e., by inhibiting cancer cell extravasation
in zebrafish at only 1 µM, thereby paving the way for future
preclinical studies.
Results
Synthesis and Characterization of Inhibitors. The compounds
employed in this study were synthesized by modular assembly
of the building blocks using established coupling protocols (40).
The required ProM scaffolds ProM-1 (41, 43), ProM-2 (45),
ProM-9 (46), ProM-13 (46), ProM-15 (47), and ProM-17 (47)
(Fig. 1B) were synthesized as separately published. The binding
of the inhibitors toward ENAH EVH1 was assessed by means of
fluorescence titration as described in SI Appendix. The obtained
Kd and the change of free energy upon binding (∆G) are given
in Table 1.
Initial Considerations. As mentioned above, inhibitor 1 served
as the starting point for ligand optimization. It represents the
pentapeptide core recognition motif wt1 of the high-affinity
Fig. 1. (A) Structure of the first-generation Ena/VASP EVH1 inhibitor 1.
All compositions share the N-acetylated 2-chloro-phenylalanine unit (blue)
attached to a central ProM-2 scaffold (red). Esterification of the C terminus
renders the inhibitors cell-membrane permeable (40). (B) General (modu-
lar) architecture of nonpeptidic, conformationally preorganized inhibitors
used in this study. Structural variation (pink) was achieved by replacing the
C-terminal ProM-1 unit (green) by ProM-9, ProM-13, ProM-12, ProM-15, or
ProM-17 (Table 1).
ActA-derived wt2 (Table 1). Comparing the affinities of 1
and the chimeric peptide 2 toward ENAH EVH1 reveals that
truncation of the flanking residues significantly contributes to
the binding with about –8 kJ/mol. Binding studies with selec-
tively truncated peptides 2∆N or 2∆C lacking either the N-
or C-terminal flanking residues indicated that the C-terminal
TEDEL−NH2 portion was almost solely responsible for the
observed affinity loss with respect to 2 (Table 1). The find-
ing confirmed a previous presumption that the terminal amino
acids Glu-Leu of TEDEL represent an additional binding epi-
tope of VASP EVH1 (49). Noteworthy, earlier attempts to gain
structural insights into the binding mechanism of C-terminally
elongated peptides had failed (50), and docking studies are
unreliable since the protein surface on the C-terminal side of
the binding groove is nearly featureless. Therefore, we first
focused on elucidating the structural details of the TEDEL
interaction with the protein surface as a precondition for the
design of analogs of the parent inhibitor 1 with improved
affinity.
Crystal Structures of ENAH EVH1 in Complex with TEDEL-Containing
Chimeras. Initial attempts to cocrystallize the N-terminally trun-
cated wild-type 10-mer Ac–1FPPPPTEDEL−NH2 with ENAH
EVH1 failed. However, replacing 1Phe by Trp or 2-Cl-Phe and/or
substituting 4PP by ProM-1 increased the affinity and yielded
crystal structures with resolution limits up to 1.0 Å (SI Appendix,
Fig. S4A). The structures unambiguously revealed that TEDEL
adopts an α-helical loop conformation exposing acidic residues
to the solvent and positioning the terminal 9EL over the protein
surface in close vicinity to the core recognition motif (Fig. 2A and
SI Appendix, Figs. S4–S8).
A closer analysis of the interaction between the TEDEL
loop and the protein surface shows that the carboxylate group
of 9Glu forms a hydrogen bond to the backbone amide of
Trp23 (W23NH), thereby displacing a highly conserved water
molecule found in every complex structure of inhibitors miss-
ing TEDEL (Fig. 2B). The helical loop conformation suggested
that the sidechain length of 9Glu is needed to properly place
the carboxylate group over W23NH. Consequently, mutating
9Glu to 9Asp decreased the binding affinity by a factor of 3
(SI Appendix, Fig. S4C). The polar interaction site of 9Glu
is separated by 8 Å from a nonpolar patch that contacts the
terminal 10Leu. The patch is mainly defined by Met14 and
extends toward the hydrophobic binding groove, where Phe77
contacts 5Pro with high specificity (SI Appendix, Fig. S3). Due
to the helix pitch of TEDEL, a long hydrophobic amino acid
is needed to contact Met14 (Fig. 2C). Consequently, mutat-
ing 10Leu to 10Ala results in nearly three times weaker binding
(SI Appendix, Fig. S4C). The ligand sidechains 5Pro and 10Leu
shield the hydrophobic interaction site entirely from solvent (SI
Appendix, Fig. S8). The coverage area of the last two prolines
4Pro and 5Pro can be enlarged by replacing them with ProM-
1 which leads to a gain of –3.5 kJ/mol of binding energy (SI
Appendix, Tables S7 and S8 and Fig. S11). Interestingly, ProM-
1 and TEDEL appear to be two independent affinity-driving
elements as the TEDEL conformation remains unaltered in
ProM-containing chimeras (SI Appendix, Fig. S4B) and TEDEL-
elongated inhibitors still bound canonically to the binding groove
(Fig. 2D).
Having analyzed the contribution of the terminal 9EL residues
by means of high-resolution crystal structures of TEDEL-
containing ligands in complex with ENAH EVH1, the next task
was to exploit this knowledge in the design of improved analogs
of the parent inhibitor 1. Specifically, we sought to modify the
C-terminal ProM-1 unit to also address the additional, so far
uncovered, polar and nonpolar interaction sites.


























Table 1. Affinities of various inhibitors toward ENAH EVH1 determined by fluorescence
titration
Ligand composition Kd, µM ∆G, kJ/mol
wt1 Ac–FPPPP–OEt 153 (8) –21.9 (0.1)
wt2 Ac–SFEFPPPPTEDEL−NH2 13.0 (0.6) –27.9 (0.1)
1 Ac–[2-Cl-Phe][ProM-2][ProM-1]–OEt 4.1 (0.3) –30.8 (0.2)
1a Ac–[2-Cl-Phe][ProM-2][ProM-1]–OMe 4.4 (0.7) –30.6 (0.4)
1b Ac–[2-Cl-Phe][ProM-2][ProM-1]–OH 2.3 (0.2) –32.2 (0.2)
2 Ac–SFE[2-Cl-Phe][ProM-2][ProM-1]TEDEL−NH2 0.15 (0.02) –38.9 (0.2)
2∆N Ac–[2-Cl-Phe][ProM-2][ProM-1]TEDEL−NH2 0.33 (0.04) –37.0 (0.3)
2∆C Ac–SFE[2-Cl-Phe][ProM-2][ProM-1]–OEt 2.9 (0.2) –31.6 (0.1)
3a Ac–[2-Cl-Phe][ProM-2][ProM-12]–OMe 15 (1) –27.6 (0.2)
3b Ac–[2-Cl-Phe][ProM-2][ProM-12]–OH 13.5 (0.4) –27.8 (0.1)
4a Ac–[2-Cl-Phe][ProM-2][ProM-15]–OMe 0.47 (0.03) –36.1 (0.1)
4b Ac–[2-Cl-Phe][ProM-2][ProM-15]–OH 0.32 (0.04) –37.0 (0.3)
5a Ac–[2-Cl-Phe][ProM-2][ProM-17]–OMe 0.53 (0.09) –35.8 (0.4)
6 Ac–[2-Cl-Phe][ProM-2][ProM-9]–OEt 0.38 (0.05) –36.6 (0.3)
6b Ac–[2-Cl-Phe][ProM-2][ProM-9]–OH 0.12 (0.02) –39.5 (0.3)
6c Ac–[2-Cl-Phe]PP[ProM-9]–OH 0.23 (0.05) –37.9 (0.5)
7 Ac–[2-Cl-Phe][ProM-2][ProM-13]–OEt 0.12 (0.01) –39.5 (0.3)
Kd and ∆G values are given with the standard errors in parentheses.
Inhibitors 3, 4, and 5 Access the Polar Hot Spot. To mimic the polar
interaction of 9Glu with W23NH, docking studies suggested
that the configurational inversion of the C-terminal carboxyl
substituent could improve binding through directly contacting
the H2O bound to W23NH (Fig. 2B). We therefore synthe-
sized ProM-12 (epi-ProM-1) and the corresponding inhibitors
3a and 3b (methyl ester or free acid; Table 1) with the termi-
nal carboxylic group now pointing toward the protein surface.
Even though these inhibitors established a 2.7-Å-long H-bond
to the bound water molecules as intended (Fig. 3 A and B),
both inhibitors 3a and 3b lost significant affinity relative to their
parent congeners 1a and 1b (Table 1). This decreased affinity
is reflected in the complex structures of 3a and 3b with res-
olution limits up to 1.42 Å by a detachment of the modified
C-terminal part of the inhibitors from the hydrophobic pro-
tein surface locally defined by the Trp23 and Phe77 sidechains
(Fig. 3B).
To address the polar hot spot while keeping the hydropho-
bic contact in the C-terminal area undisturbed, docking studies
suggested to formally open the C-terminal pyrrolidine ring of
inhibitor 1 or 3. Such a modification opened the possibility to
probe the underlying hydrophobic binding groove with different
moieties (ProM-15 and ProM-17; Fig. 1B) (47). The result-
ing less rigid inhibitors 4a and 5a showed a greatly improved
affinity toward ENAH EVH1 by –5.5 kJ/mol compared to 1a,
thereby nearly restoring the binding energy of the TEDEL-
containing chimera 2∆N (Table 1). The complex structures of
4a and 4b with resolution limits up to 1.1 Å confirmed that
the “ethyl finger” of ProM-15 indeed established the contact
with the hydrophobic binding groove while the ester function
maintained a 2.7-Å-long H-bond contact with the water bound
to W23NH (Fig. 3C and SI Appendix, Fig. S9). Even though
inhibitor 5a was expected to further enhance affinity by cov-
ering the hydrophobic area with an isobutyl group, it bound
just as well as 4a. The structure of 5a in complex with ENAH
EVH1 at a resolution limit of 0.78 Å revealed the sterically more
demanding ProM-17 scaffold being a bit too bulky, causing the
inhibitor to be N-terminally shifted away from the ideal posi-
tion (Fig. 3 C and D). Consequently, the H-bond contact to
the W23NH-bound water widened to 3.0 Å. Due to the lack of
affinity gain, inhibitor 5a was not investigated further in cellular
assays.
Inhibitors 6 and 7 Cover the Hydrophobic Patch. The results
obtained with the ProM-12–, ProM-15–, and ProM-17–derived
inhibitors emphasize the particular importance to properly cover
the hydrophobic binding site spanned by Phe77 and Met14 rather
than accessing the H2O bound to W23NH (Fig. 3D). As indi-
cated by docking studies we envisioned that this hydrophobic
hot spot could be specifically accessed by equipping 1 with an
Fig. 2. Crystal structure of chimera 2∆N in complex with ENAH EVH1
reveals the TEDEL loop binding close to the main binding groove through
polar and nonpolar interactions. (A) Interaction sites of terminal EL. 2∆N
is displayed as ribbon and transparent sticks, color coded by a secondary
structure element: PPII (blue) and α-helix (yellow). (B) The backbone amide
nitrogen of W23 is contacted by either 9Glu or a conserved water molecule
(superposition of 19 H2O from 12 asymmetric units). (C) The hydrophobic
site provided by M14 and F77 is reachable only by a long aliphatic amino
acid such as 10Leu. (D) Superposition of inhibitor 1b (white) and 2∆N (blue-
yellow). View along the main binding groove reveals only minor ligand
rearrangements.

















































Fig. 3. Crystal structures of ENAH EVH1 in complex with ProM-12–,
ProM-15–, and ProM-17–containing inhibitors. The solvent-accessible sur-
face of ENAH EVH1 is color coded by hydrophobicity (blue-white-red for
hydrophilic–hydrophobic). (A) Superposition of 2∆N (white) and the ProM-
12–containing inhibitors 3a and 3b (green). (B) Detailed view highlighting
the disturbed contact of the carboxyl substituent of 3a and 3b to their
respective bound water molecules (red spheres) associated to an unfavor-
able detachment from the W23 sidechain in comparison to 2∆N (white). (C)
Superposition of 2∆N (white) with inhibitors 4a (light green) and 5a (dark
green). (D) Detailed view illustrating the capability of ProM-15 (4a) and
ProM-17 (5a) to address the hydrophobic groove while maintaining contact
to their respective bound water molecules (red spheres).
additional alkyl substituent at the C-terminal pyrrolidine ring.
For this reason the alkylated derivatives of ProM-1, i.e., ProM-
9 and ProM-13 (Fig. 1B), were synthesized (46) and used to
prepare the desired inhibitors 6 and 7 (Table 1). Affinity mea-
surements then showed that both inhibitors outperformed 1
substantially and lowered the Kd to 380 nM (6) and 120 nM
(7). Noteworthy, inhibitor 7 gained –8.7 kJ/mol relative to 1 and
bound equally strong as the untruncated chimera 2. Thus, by cal-
culated introduction of a single ethyl substituent we succeeded in
restoring the entire binding energy of eight flanking amino acid
residues and in coming up with a potent 734-Da inhibitor binding
canonically to all Ena/VASP EVH1 domains (SI Appendix, Table
S9). The formal alkylation of inhibitor 1 increased its molecular
weight by less than 4% and improved the ligand efficiency (51)
(SI Appendix, Table S9).
High-resolution crystal structures of ENAH EVH1 in com-
plex with inhibitors 6b and 7 at 1.02 Å resolution confirmed
that the modified scaffolds indeed accessed the hydrophobic hot
spot as intended (Fig. 4 A and B and SI Appendix, Fig. S10).
Superposition with inhibitors 2∆N, 1b, or 4a highlighted that
both optimized scaffolds showed little conformational bias and
only marginal displacements. Thus, the observed affinity boost
from 1 (Kd 4.1 µM) to 7 (Kd 0.12 µM) clearly results from prop-
erly covering Trp23, Met14, and Phe77 by the additional ethyl
substituent of ProM-13 (Fig. 4 C and D).
The Optimized Inhibitors Are Selective and Compete with Natural
Binding Partners of Ena/VASP. We first tested whether the opti-
mized inhibitors retained specificity toward Ena/VASP EVH1
compared to other proline-rich motif-recognizing proteins. We
used sensible 1H- 15N heteronuclear single quantum coherence
(HSQC) NMR experiments and assigned peak perturbation tra-
jectories to assess the binding affinities of 1, 4a, and 7 also against
Fyn SH3, Profilin, and Yap1 WW1 (Fig. 5A). This in turn allowed
additional structural insights into the binding mode to off-target
proteins and confirmed that all inhibitors were recognized by the
canonic interaction sites of Fyn SH3, Profilin, and Yap1 WW1,
corroborating the ability of ProM scaffolds to mimic PPII sec-
ondary structure elements (SI Appendix, Figs. S13 and S21). At
the same time, all inhibitors bound with drastically decreased
affinity to the off-target proteins compared to ENAH EVH1, and
this decrease was more prominent for the optimized inhibitors
4a and 7 (SI Appendix, Table S10), suggesting that in silico opti-
mization not only yielded highly desirable affinity boosts but also
increased the selectivity for Ena/VASP EVH1. The specificity
seen in HSQC experiments also held in a more complex environ-
ment such as the Jurkat cell lysate. Inhibitors 1, 4a, 6, and 7 were
not competing with the natural binding partner ADAP (52) for
Fyn SH3, while the synthetic peptide Ac–RPLPPLP−NH2 (53)
with a measured Kd of 8.2 µM displaced ADAP from bead-bound
GST-Fyn SH3 at the same concentration (in vitro pulldown; SI
Appendix, Fig. S22).
To probe whether the developed compounds also exhibit
the expected biological activity, we investigated their effect on
triple-negative (estrogen receptor-, progesterone receptor-, and
HER2-negative) breast cancer cells (MDA–MB–231), which
represent a major therapeutic challenge (54). At first we assessed
the efficiency of 7 to compete with known binding partners for
Ena/VASP EVH1 by performing in vitro pulldown experiments
with MDA–MB–231 cell lysate to find that the initial (1) and
the structure-optimized (7) inhibitor were able to compete for
ENAH EVH1 with RAPH1 (16), RIAM (34), and Zyxin (55)
in a concentration-dependent manner (Fig. 5B). Analysis of the
Western blot revealed that the half-maximal inhibitory concen-
tration (IC50) of 7 was 18 times smaller than that of 1 (mean
IC50 0.67 µM vs. 12 µM, P < 0.0002).
Optimized Inhibitors Potently Inhibit Ena/VASP-Mediated Breast Can-
cer Cell Invasion. As Ena/VASP proteins are centrally involved
in the formation of protrusive structures during cell migra-
tion (16, 18) and degradation of extracellular matrix (56), we
expected that inhibiting their interaction with natural binding
partners might affect the invasiveness of cancer cells. Indeed,
incubating MDA–MB–231 with inhibitors 1, 4a, 6, and 7 reduced
chemotaxis along a fetal bovine serum (FBS) gradient in a
Fig. 4. Crystal structures of ENAH EVH1 in complex with ProM-9– and
ProM-13–containing inhibitors. The solvent-accessible surface of ENAH
EVH1 is color coded by hydrophobicity (blue-white-red for hydrophilic–
hydrophobic). (A and B) Superposition of inhibitors 6b and 7 with 2∆N
(white) shows how the additional alkylation at the C-terminal pyrrolidine
ring accesses the apolar hot spot addressed by 10Leu in 2∆N. (C) Superpo-
sition of inhibitors 7 and 1b (white) reveals little conformational bias and
marginal displacements. (D) Superposition of inhibitors 7 and 4a highlights
the coverage of F77 and W23.


























Fig. 5. In vitro studies with the initial and optimized inhibitors. (A) The 1H- 15N HSQC titration experiments to assess the off-target specificity of 1, 4a, and
7. Each inhibitor was tested against a selection of domains recognizing proline-rich segments (Fyn SH3, Profilin, and Yap1 WW) and peak perturbations
farther than 0.1 ppm were taken into account. Plotted are fitted Kd on a logarithmic scale, together with the according affinities for ENAH EVH1 taken from
Table 1. (B) Pulldown experiments and fluorescence-based analysis of GST-tagged ENAH EVH1 from MDA–MB–231 cell lysates treated with 1 or 7. Natural
binding partners RAPH1, RIAM, and Zyxin are displaced by the inhibitors from ENAH EVH1 in a concentration-dependent manner with different IC50 values
(P = 1.6e-4).
dose-dependent manner (Fig. 6A and SI Appendix, Fig. S23).
The calculated IC50 values confirmed that optimized inhibitors
exhibit a superior potency compared to 1 (Fig. 6 A, Right; mean
IC50 1, 88 µM; 4a, 53 µM; 6, 24 µM; and 7, 26 µM). The
increased potency of 7 was also confirmed in a Boyden chamber
invasion assay (SI Appendix, Fig. S24). To exclude possible toxic
effects, we tested inhibitors 1, 4a, 6, and 7 in MDA–MB–231 but
also Ena/VASP triple-knockout mouse fibroblastic MVD7 and
Ena/VASP triple-knockout mouse melanoma cell lines. None
of the cell lines showed toxic effects at 180 µM (SI Appendix,
Fig. S25).
To determine whether the increased potency seen for
inhibitors 4a, 6, and 7 also holds in vivo, we investigated their
effect on the extravasation of MDA–MB–231 cells in trans-
genic zebrafish embryos (fli:EGFP) (57) (Fig. 6A). Simulating
the late stage of the metastatic cascade, we measured the ability
of MDA–MB–231 cells to extravasate into the avascular collagen
matrix-rich tailfin (58). Counting the number of cells that have
extravasated and invaded the tailfin tissue, we could indeed ver-
ify that inhibition of the Ena/VASP-mediated processes caused
pronounced antiinvasive effects (Fig. 6B). In contrast to the ini-
tial inhibitor 1, which at 1 µM concentration did not show any
effect compared to zebrafish treated with phosphate-buffered
saline (PBS) (P > 0.2), the structure-optimized inhibitors signifi-
cantly reduced cancer cell extravasation (4a and 7, P < 0.0001; 6,
P < 0.005). Surprisingly, the weaker binding inhibitor 4a exhib-
ited a similarly strong in vivo activity to that of 7 probably due to
different secondary properties such as cell permeability. These
data indicate that the structure-based optimization of our EVH1
inhibitors (Fig. 1B) not only resulted in a gain of binding affin-
ity but also opened options to fine-tune their pharmacological
properties.
Discussion
Based on recent evidence that Ena/VASP is a critical factor in
metastatic cancer progression, we targeted its EVH1 adapter
domain which recognizes proline-rich segments on a shallow,
rigidly shaped, and nearly featureless protein surface. The chal-
lenge to develop a small molecule inhibitor for this seemingly
“undruggable” protein–protein interaction was successfully met
by combining X-ray crystallography, in silico design, and chem-
ical synthesis of modular inhibitors displaying a preorganized
PPII secondary structure. To extend our toolbox of conforma-
tionally defined proline-derived synthetic scaffolds (ProMs) we
first identified two affinity-driving hot spots on the surface of
ENAH EVH1 by characterizing the binding mode of TEDEL-
elongated ligands. In a second step we then specifically modified
our initial inhibitor 1 to exploit these interaction sites: The
ProM-15– and ProM-17–derived inhibitors 4a and 5a, designed
to contact the discovered polar hot spot, showed an impressive
gain of affinity (Kd of 470 and 530 nM, respectively). These
compounds were even surpassed by the ProM-9– and ProM-
13–derived inhibitors 6 and 7, designed to cover a hydrophobic
patch, the latter binding to ENAH EVH1 with a Kd of 120 nM.
Thus, by calculated introduction of a single ethyl substituent
close to the C terminus of 1 we could gain as much binding

















































Fig. 6. Cellular and in vivo studies with the initial and optimized inhibitors. (A) IncuCyte chemotaxis assay with inhibitor-treated MDA–MB–231. (Left)
Invasion is inhibited in a dose-dependent manner (representative phase object count, normalized to fitted IC50 curves with 3σ dashed line). (Right) IC50s
were calculated during linear phase object signal increase of the assay and are plotted as a group. (B) MDA–MB–231 cancer cells extravasation in zebrafish
treated with PBS (control) or inhibitors 1, 4a, 6, or 7 at 1 µM concentration. (C) Representative fluorescence images of zebrafish embryos taken on day 5.
MDA–MB–231 (red) extravasate into the avascular tailfin (white arrows).
energy as contributed by the eight flanking amino acid residues
of the chimeric ligand 2. Furthermore, we showed that the
structure-optimized inhibitors compete with known Ena/VASP
interaction partners and exhibit increased selectivity for the
EVH1 domain compared to related proline-rich recognizing pro-
teins, both in vitro and in a complex environment such as the
Jurkat cell lysate. All optimized inhibitors 4a, 6, and 7 interfere
with the invasion of MDA–MB–231 cells with increased potency
compared to the initial inhibitor 1. Finally, we could demonstrate
the ability of the optimized compounds to inhibit cancer cell
extravasation in vivo in a zebrafish model at 1 µM concentration.
This way, we proved that synthetic Ena/VASP EVH1 inhibitors
exhibit biological activity also beyond cellular assays.
Materials and Methods
Protein Purification. Ena/VASP EVH1 domains were expressed as GST-fusion
proteins in E. coli BL21(DE3) grown in 2YT medium overnight. After sonifi-
cation and centrifugation the soluble fraction was loaded on a glutathione
Sepharose matrix and eluted with GSH. GST was cleaved overnight with
thrombin and loaded on an SP Sepharose ion exchange column and
rebuffered by passing over a HiLoad 16/60 Superdex 75 size exclusion
column.
Crystallization. Crystals were obtained by sitting vapor diffusion using
microseeding and 8 to 26 mg/mL ENAH EVH1 at 293 to 300 K with
different ligand excess. All structures were solved by molecular replace-
ment, refined by the PHENIX program suite, and deposited at the Protein
Data Base databank. Diffraction and refinement statistics and the acces-
sion codes are listed in SI Appendix, Tables S1–S6. Complex structures
were superposed by rigid body match using the five atomic positions
W23NE, W23N, F77CG, Y16CG, and Q79CD and images were rendered in
Chimera.
Binding Studies. Dissociation constants were determined via fluorescence
titration or isothermal titration calorimetry at 298 K in 40 mM sodium
phosphate, pH 7.3, 100 mM NaCl, and 2 mM TCEP. HSQC NMR spectra
were recorded on a Bruker AV600 at 300 K with 16 scans, data size 1,024
( 1H) × 256 ( 15N), and peak perturbation trajectories were tracked in
Sparky.
Pulldown Assay. GST-ENAH EVH1 or GST-Fyn SH3 were immobilized on glu-
tathione Sepharose 4B beads using MDA–MB–231 or Jurkat cell lysate.
Displacement of natural binding partners was achieved by adding inhibitors
to the lysate incubating overnight on beads at 4 ◦C. The Western blot with
target-specific antibodies was read out by a fluorescence-based secondary
antibody on an infrared scanner.


























IncuCyte Assay. Migration of 2,000 cells per well was monitored by the
IncuCyte S3 live cell imaging system over a gradient of 0.25% FBS (insert)
to 1% FBS (lower chamber) in Dulbecco’s Modified Eagle Medium (DMEM)
high-glucose medium, with the inhibitors supplied in both chambers. The
experiment was set up as a triplet for the inhibitor concentrations and
quadruplets for the positive (PBS) and negative controls (20 µM PI3K
inhibitor LY294002). Raw data were averaged and processed with a script
written in R language.
Zebrafish Assay. mCherry-labeled MDA–MB–231 were injected into the duct
of curvier of transgenic zebrafish embryos (fli:EGFP) and administrated with
corresponding inhibitor treatment. Zebrafish embryos were maintained at
34 ◦C and the numbers of MDA–MB–231 cells that extravasated individually
from circulation into the collagen fibers of the tail fin were counted 5 d
postinjection.
Data and Code Availability. All study data are included in this article and SI
Appendix.
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